Saalfeld, Felix C., Wenzel, Carina ORCID: 0000-0001-5869-6934, Christopoulos, Petros ORCID: 0000-0002-7966-8980, Merkelbach-Bruse, Sabine, Reissig, Timm M., Lassmann, Silke, Thiel, Sebastian, Stratmann, Jan A., Marienfeld, Ralf, Berger, Johannes, Desuki, Alexander, Velthaus, Janna-Lisa, Kauffmann-Guerrero, Diego, Stenzinger, Albrecht, Michels, Sebastian, Herold, Thomas, Kramer, Michael, Herold, Sylvia, Tufman, Amanda, Loges, Sonja ORCID: 0000-0002-7650-8527, Alt, Jurgen, Joosten, Maria, Schmidtke-Schrezenmeier, Gerlinde, Sebastian, Martin, Stephan-Falkenau, Susann, Waller, Cornelius F., Wiesweg, Marcel, Wolf, Juergen, Thomas, Michael, Aust, Daniela E. and Wermke, Martin (2021). Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. J. Thorac. Oncol., 16 (11). S. 1952 - 1959. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Full text not available from this repository.

Abstract

Introduction: In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2-mutated NSCLC (HER2mu NSCLC). Nevertheless, several compounds have revealed promising early efficacy data, which need to be evaluated in the context of current standard approaches. Although data on the efficacy of immune checkpoint inhibitors (ICIs) in second or subsequent lines of treatment remain limited and conflicting, there are virtually no data on patient outcome under ICI/platinum-doublet combinations in the first-line setting. Methods: We retrospectively evaluated outcomes of patients with HER2mu NSCLC treated with ICI alone or in combination with chemotherapy within the German National Network Genomic Medicine Lung Cancer consortium by means of overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: ICI either in combination with chemotherapy or as monotherapy was applied as first-line treatment in 27 patients, whereas 34 received single-agent ICI in second or subsequent lines. Patient characteristics were in line with previously published data. In treatment-naive patients receiving ICI in combination with chemotherapy, the ORR, median PFS, and OS rate at 1 year were 52%, 6 months, and 88%, respectively. In second or subsequent lines, ICI monotherapy was associated with an ORR of 16%, a median PFS of 4 months, and a median OS of 10 months. Conclusions: ICIs are effective as monotherapy and in combination with platinum-doublet chemotherapy. Therefore, ICI-based treatments may be found as the current standard of care and benchmark for targeted therapies in HER2mu NSCLC. (C) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Saalfeld, Felix C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wenzel, CarinaUNSPECIFIEDorcid.org/0000-0001-5869-6934UNSPECIFIED
Christopoulos, PetrosUNSPECIFIEDorcid.org/0000-0002-7966-8980UNSPECIFIED
Merkelbach-Bruse, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reissig, Timm M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lassmann, SilkeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thiel, SebastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stratmann, Jan A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Marienfeld, RalfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Berger, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Desuki, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Velthaus, Janna-LisaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kauffmann-Guerrero, DiegoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stenzinger, AlbrechtUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Michels, SebastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herold, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kramer, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herold, SylviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tufman, AmandaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loges, SonjaUNSPECIFIEDorcid.org/0000-0002-7650-8527UNSPECIFIED
Alt, JurgenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Joosten, MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidtke-Schrezenmeier, GerlindeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sebastian, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stephan-Falkenau, SusannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waller, Cornelius F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wiesweg, MarcelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomas, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aust, Daniela E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wermke, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-605567
DOI: 10.1016/j.jtho.2021.06.025
Journal or Publication Title: J. Thorac. Oncol.
Volume: 16
Number: 11
Page Range: S. 1952 - 1959
Date: 2021
Publisher: ELSEVIER SCIENCE INC
Place of Publication: NEW YORK
ISSN: 1556-1380
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
LUNG-CANCER; HER2Multiple languages
Oncology; Respiratory SystemMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60556

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item